Pierre Fabre is paying Scorpion Therapeutics $65 million to begin a partnership on clinical development and potential commercialization of two targeted therapies for non-small cell lung cancer. The Scorpion drugs could have safety advantages over approved Johnson & Johnson and Takeda therapies that address the same rare genetic signature.
Scorpion receives $65 million from an upfront payment and the achievement of near-term milestones and is eligible to receive up to $553 million in potential milestones, plus royalties on net product
Scorpion receives $65 million from an upfront payment and the achievement of near-term milestones and is eligible to receive up to $553 million in potential milestones, plus royalties on net
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.